208 related articles for article (PubMed ID: 20820870)
1. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951.
Idbaih A; Dalmasso C; Kouwenhoven M; Jeuken J; Carpentier C; Gorlia T; Kros JM; French P; Teepen J; Broët P; Delattre O; Mokhtari K; Sanson M; Delattre JY; van den Bent M; Hoang-Xuan K
J Neurooncol; 2011 Jun; 103(2):221-30. PubMed ID: 20820870
[TBL] [Abstract][Full Text] [Related]
2. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
Kouwenhoven MC; Gorlia T; Kros JM; Ibdaih A; Brandes AA; Bromberg JE; Mokhtari K; van Duinen SG; Teepen JL; Wesseling P; Vandenbos F; Grisold W; Sipos L; Mirimanoff R; Vecht CJ; Allgeier A; Lacombe D; van den Bent MJ
Neuro Oncol; 2009 Dec; 11(6):737-46. PubMed ID: 19224764
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
van den Bent MJ; Brandes AA; Taphoorn MJ; Kros JM; Kouwenhoven MC; Delattre JY; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Enting RH; French PJ; Dinjens WN; Vecht CJ; Allgeier A; Lacombe D; Gorlia T; Hoang-Xuan K
J Clin Oncol; 2013 Jan; 31(3):344-50. PubMed ID: 23071237
[TBL] [Abstract][Full Text] [Related]
4. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951.
Gorlia T; Delattre JY; Brandes AA; Kros JM; Taphoorn MJ; Kouwenhoven MC; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; van den Bent MJ
Eur J Cancer; 2013 Nov; 49(16):3477-85. PubMed ID: 23896377
[TBL] [Abstract][Full Text] [Related]
5. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
van den Bent MJ; Dubbink HJ; Sanson M; van der Lee-Haarloo CR; Hegi M; Jeuken JW; Ibdaih A; Brandes AA; Taphoorn MJ; Frenay M; Lacombe D; Gorlia T; Dinjens WN; Kros JM
J Clin Oncol; 2009 Dec; 27(35):5881-6. PubMed ID: 19901104
[TBL] [Abstract][Full Text] [Related]
6. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
van den Bent MJ; Dubbink HJ; Marie Y; Brandes AA; Taphoorn MJ; Wesseling P; Frenay M; Tijssen CC; Lacombe D; Idbaih A; van Marion R; Kros JM; Dinjens WN; Gorlia T; Sanson M
Clin Cancer Res; 2010 Mar; 16(5):1597-604. PubMed ID: 20160062
[TBL] [Abstract][Full Text] [Related]
7. Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
Erdem-Eraslan L; Gravendeel LA; de Rooi J; Eilers PH; Idbaih A; Spliet WG; den Dunnen WF; Teepen JL; Wesseling P; Sillevis Smitt PA; Kros JM; Gorlia T; van den Bent MJ; French PJ
J Clin Oncol; 2013 Jan; 31(3):328-36. PubMed ID: 23269986
[TBL] [Abstract][Full Text] [Related]
8. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.
van den Bent MJ; Looijenga LH; Langenberg K; Dinjens W; Graveland W; Uytdewilligen L; Sillevis Smitt PA; Jenkins RB; Kros JM
Cancer; 2003 Mar; 97(5):1276-84. PubMed ID: 12599236
[TBL] [Abstract][Full Text] [Related]
9. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
; Cairncross G; Berkey B; Shaw E; Jenkins R; Scheithauer B; Brachman D; Buckner J; Fink K; Souhami L; Laperierre N; Mehta M; Curran W
J Clin Oncol; 2006 Jun; 24(18):2707-14. PubMed ID: 16782910
[TBL] [Abstract][Full Text] [Related]
10. Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951.
Mokhtari K; Ducray F; Kros JM; Gorlia T; Idbaih A; Taphoorn M; Wesseling P; Hoang-Xuan K; Van den Bent M; Sanson M
Cancer; 2011 Jul; 117(13):3014-26. PubMed ID: 21246521
[TBL] [Abstract][Full Text] [Related]
11. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
van den Bent MJ; Carpentier AF; Brandes AA; Sanson M; Taphoorn MJ; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Haaxma-Reiche H; Kros JM; van Kouwenhoven MC; Vecht CJ; Allgeier A; Lacombe D; Gorlia T
J Clin Oncol; 2006 Jun; 24(18):2715-22. PubMed ID: 16782911
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
[TBL] [Abstract][Full Text] [Related]
14. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402.
Giannini C; Burger PC; Berkey BA; Cairncross JG; Jenkins RB; Mehta M; Curran WJ; Aldape K
Brain Pathol; 2008 Jul; 18(3):360-9. PubMed ID: 18371182
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.
Buckner JC; Gesme D; O'Fallon JR; Hammack JE; Stafford S; Brown PD; Hawkins R; Scheithauer BW; Erickson BJ; Levitt R; Shaw EG; Jenkins R
J Clin Oncol; 2003 Jan; 21(2):251-5. PubMed ID: 12525516
[TBL] [Abstract][Full Text] [Related]
16. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
Walker C; Haylock B; Husband D; Joyce KA; Fildes D; Jenkinson MD; Smith T; Broome J; du Plessis DG; Warnke PC
Neurology; 2006 Jun; 66(11):1661-7. PubMed ID: 16769937
[TBL] [Abstract][Full Text] [Related]
17. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
Cairncross JG; Ueki K; Zlatescu MC; Lisle DK; Finkelstein DM; Hammond RR; Silver JS; Stark PC; Macdonald DR; Ino Y; Ramsay DA; Louis DN
J Natl Cancer Inst; 1998 Oct; 90(19):1473-9. PubMed ID: 9776413
[TBL] [Abstract][Full Text] [Related]
18. The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients.
Hacisalihoglu P; Kucukodaci Z; Gundogdu G; Bilgic B
Turk Neurosurg; 2017; 27(5):682-689. PubMed ID: 27651340
[TBL] [Abstract][Full Text] [Related]
19. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.
Cairncross JG; Wang M; Jenkins RB; Shaw EG; Giannini C; Brachman DG; Buckner JC; Fink KL; Souhami L; Laperriere NJ; Huse JT; Mehta MP; Curran WJ
J Clin Oncol; 2014 Mar; 32(8):783-90. PubMed ID: 24516018
[TBL] [Abstract][Full Text] [Related]
20. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
Cairncross G; Wang M; Shaw E; Jenkins R; Brachman D; Buckner J; Fink K; Souhami L; Laperriere N; Curran W; Mehta M
J Clin Oncol; 2013 Jan; 31(3):337-43. PubMed ID: 23071247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
